It is still unclear if FXII is a bona fide cancer driver but it shares remarkable similarities with the activation of uPAR by urokinase plasminogen activator (uPA), an important driver of epithelial-mesenchymal transition in breast cancer [62, 63]. This evidence concerns the gene PLAU and cancer.